Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD
← catalyst calendarNCT07435129 · readout ≤ 681 d
Sponsored by Scholar Rock, Inc. (industry) · SRRK — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
60estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-30 | actual | When the study began enrolling |
| Primary completion | Jun 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Facioscapulohumeral Muscular Dystrophy
- FSHD
Interventions
- Drug: Apitegromab — also filed as SRK-015
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFAssess the efficacy of apitegromab compared with placebo in participants with FSHD
measured 52 Weeks
Permalink · SRRK's whole pipeline · Catalyst calendar · Every registered study · What changed